Mike Montemarano, Associate Editor 03.22.21
Deerland Probiotics and Enzymes recently announced the publication of a new clinical trial in the International Journal of Molecular Sciences examining the immune support effects of Bacillus subtilis DE111, in a randomized, double-blind, placebo-controlled study involving 44 healthy adults between the ages of 20 and 62. The researchers examined peripheral blood mononuclear cells (PBMCs) at basal levels pre- and post-study, as well as in response to stimulation with bacterial lipopolysaccharide (LPS), which encourages neutrophils, macrophages, and other innate immune cells to release pro-inflammatory cytokines. The results of the study indicated that DE111 can support a healthy immune system and robust immune response, Deerland said.
Following a four week supplementation period, participants displayed immunomodulatory and anti-inflammatory effects on several T cell subsets.
“This is supported by the observed reduction in immune cell populations within the basal state,” the authors wrote. “The downregulation of these cell types in circulation may implicate an overall anti-inflammatory state demonstrated by the decrease in peripheral surveillance and effector cell types.”
Another proposed mechanism suggests that DE111 ingestion improved the gut barrier function resulting in less circulating LPS, thereby reducing inflammation levels. In addition, the authors found those in the DE111 group exhibited an increase in anti-inflammatory immune cell populations in response to ex vivo LPS stimulation of PBMCs, which is indicative of a more robust response to prime the immune system.
In summary, they said that supplementing with B. subtilis DE111 “modulates the host immune system through anti-inflammatory and suppressive action on both innate and adaptive cell types.”
“This newly published study substantiates the efficacy of B. subtilis DE111 for use in products that address the most common concerns of the day – a strong immune system with a quick response to foreign invaders,” Dr. John Deaton, vice president of science and technology at Deerland Probiotics and Enzymes said. “The latest publication adds to an impressive list of clinical studies showing DE111’s impact on digestive, children’s and cardio health and sports performance/recovery.”
Mike Montemarano has been the Associate Editor of Nutraceuticals World since February 2020. He can be reached at mmontemarano@rodmanmedia.com.
Following a four week supplementation period, participants displayed immunomodulatory and anti-inflammatory effects on several T cell subsets.
“This is supported by the observed reduction in immune cell populations within the basal state,” the authors wrote. “The downregulation of these cell types in circulation may implicate an overall anti-inflammatory state demonstrated by the decrease in peripheral surveillance and effector cell types.”
Another proposed mechanism suggests that DE111 ingestion improved the gut barrier function resulting in less circulating LPS, thereby reducing inflammation levels. In addition, the authors found those in the DE111 group exhibited an increase in anti-inflammatory immune cell populations in response to ex vivo LPS stimulation of PBMCs, which is indicative of a more robust response to prime the immune system.
In summary, they said that supplementing with B. subtilis DE111 “modulates the host immune system through anti-inflammatory and suppressive action on both innate and adaptive cell types.”
“This newly published study substantiates the efficacy of B. subtilis DE111 for use in products that address the most common concerns of the day – a strong immune system with a quick response to foreign invaders,” Dr. John Deaton, vice president of science and technology at Deerland Probiotics and Enzymes said. “The latest publication adds to an impressive list of clinical studies showing DE111’s impact on digestive, children’s and cardio health and sports performance/recovery.”
Mike Montemarano has been the Associate Editor of Nutraceuticals World since February 2020. He can be reached at mmontemarano@rodmanmedia.com.
